

SECURITIES AND EXCHANGE COMMISSION

FORM 3

Filing Date: **2013-01-09** | Period of Report: **2013-01-01**
SEC Accession No. [0001225208-13-001254](#)

(HTML Version on secdatabase.com)

REPORTING OWNER

MADDALUNA ANTHONY J

CIK: **1566333**

Type: **3** | Act: **34** | File No.: **001-03619** | Film No.: **13521290**

Mailing Address
PFIZER INC. ATTN
CORPORATE SECRETARY
235 RAST 42ND STREET
NEW YORK NY 10017

ISSUER

PFIZER INC

CIK: **78003** | IRS No.: **135315170** | State of Incorporation: **DE** | Fiscal Year End: **1231**
SIC: **2834** Pharmaceutical preparations

Mailing Address
235 E 42ND ST
NEW YORK NY 10017

Business Address
235 E 42ND ST
NEW YORK NY 10017
2125732323

FORM 3**UNITED STATES SECURITIES AND
EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: 02/28/2011
Estimated average burden
hours per response 0.5**INITIAL STATEMENT OF BENEFICIAL
OWNERSHIP OF SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section
17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the
Investment Company Act of 1940

1. Name and Address of Reporting Person MADDALUNA ANTHONY J (Last) (First) (Middle) PFIZER INC.-CORP. SECRETARY, 235 EAST 42ND ST. (Street) NEW YORK, NY 10017 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/ Year) 01/01/2013	3. Issuer Name and Ticker or Trading Symbol PFIZER INC [PFE]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Executive Vice President	5. If Amendment, Date Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check applicable line) <input checked="" type="checkbox"/> Form Filed by One Reporting Person <input type="checkbox"/> Form Filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	57,988	D	
Common Stock	44,269	I	By Rule 16b-3 Plan

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	(1)	02/21/2017	Common Stock	43,500	\$25.87	D	
Employee Stock Option (right to buy)	(1)	02/22/2016	Common Stock	58,000	\$26.2	D	
Employee Stock Option (right to buy)	(1)	02/23/2015	Common Stock	34,000	\$26.2	D	
Employee Stock Option (right to buy)	(1)	02/26/2013	Common Stock	20,000	\$29.33	D	
Employee Stock Option (right to buy)	(1)	02/25/2014	Common Stock	34,000	\$37.15	D	
Phantom Stock Units SSP	(2)	(2)	Common Stock	33,437	(3)	D	
Stock Appreciation Rights	02/26/2014 (4)	02/26/2014 (4)	Common Stock	20,460	\$12.7	D	
Stock Appreciation Rights	02/25/2015 (4)	02/25/2015 (4)	Common Stock	23,649	\$17.69	D	

Stock Appreciation Rights	12/31/2014 ⁽⁴⁾	12/31/2014 ⁽⁴⁾	Common Stock	26,767	\$18.19	D	
Stock Appreciation Rights	02/24/2016 ⁽⁴⁾	02/24/2016 ⁽⁴⁾	Common Stock	62,453	\$18.9	D	
Stock Appreciation Rights	02/24/2018 ⁽⁵⁾	02/24/2018 ⁽⁵⁾	Common Stock	51,702	\$18.9	D	
Stock Appreciation Rights	02/23/2017 ⁽⁴⁾	02/23/2017 ⁽⁴⁾	Common Stock	65,534	\$21.03	D	
Stock Appreciation Rights	02/23/2019 ⁽⁵⁾	02/23/2019 ⁽⁵⁾	Common Stock	55,556	\$21.03	D	
Stock Appreciation Rights	02/28/2013 ⁽⁴⁾	02/28/2013 ⁽⁴⁾	Common Stock	17,140	\$22.55	D	

Explanation of Responses:

1. These options are fully exercisable.
2. These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.
3. Each unit represents one phantom share of common stock.
4. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant.
5. The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant.

Remarks:

poaam12.htm

Signatures

Lawrence A. Fox, by power of atty., for Anthony J. Maddaluna

** Signature of Reporting Person

01/09/2013

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints each of Lawrence A. Fox, Tara J. Gabbai, Claire G. Keyles, Matthew Lepore and Madelyn D. Purcell as the undersigned's true and lawful attorney-in-fact and agent, and grants each of them full power to act on behalf of the undersigned and in the undersigned's name, place and stead, in any and all capacities, for the purpose of completing and signing, on behalf of the undersigned,

- any Form 3, Form 4 or Form 5 required or permitted to be filed by the undersigned pursuant to Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"),
- any Form 144 required to be filed by the undersigned under the Securities Act of 1933, as amended (the "Securities Act"), and Rule 144 promulgated thereunder, and
- any and all other documents, including, without limitation, Form ID, necessary or desirable to facilitate the filing by the undersigned of Form 144 and forms under Section 16 of the Exchange Act,

with regard to the undersigned's ownership of or transactions in securities of Pfizer Inc., including, without limitation, the power to complete and sign any and all amendments to such forms and documents, if any, and to file such forms and documents and amendments thereto with the Securities and Exchange Commission, and to do and perform each and every act and thing requisite or necessary to be done in connection with such forms and documents and amendments thereto, as fully and to all intents and purposes as the undersigned might or could do in person.

The authority of Lawrence A. Fox, Tara J. Gabbai, Claire G. Keyles, Matthew Lepore and Madelyn D. Purcell under this Power of Attorney shall continue until the undersigned is no longer required to file Form 3, Form 4, Form 5 or Form 144 with regard to the undersigned's ownership of or transactions in securities of Pfizer Inc., unless earlier revoked in writing. The undersigned acknowledges that Lawrence A. Fox, Tara J. Gabbai, Claire G. Keyles, Matthew Lepore and Madelyn D. Purcell are not assuming any of the undersigned's responsibilities to comply with Rule 144 under the Securities Act or Section 16 of the Exchange Act.

Signature: /s/ Anthony J. Maddaluna

Date: December 18, 2012